Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05525858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Study acronym: KOSMOSII
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Sep 2026 → Mar 31, 2027
See other at-risk trials from Seoul National University Bundang Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Mar 31, 2027 Show 7 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Enrollment closed, study ongoing
    • Study completion date: Mar 2027 to Mar 31, 2027
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 32 of 32 sites
    • Publications: details revised at 1 of 1 entry
  2. Site details revised at 1 of 32 sitesv14
  3. Site details revised at 4 of 32 sitesv13
  4. Site contacts updated at 5 of 32 sitesv12
  5. Primary completion date: Sep 2025 to Sep 2026
    • Study completion date: Sep 2025 to Mar 2027
    • Site contacts updated at 6 of 32 sites
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Site details revised at 1 of 32 sitesv10
  2. Study sites: 31 to 32v9
  3. Site contacts updated at 3 of 31 sitesv8
  4. Site details revised at 1 of 31 sitesv7
  5. Interventions: Alectinib (Drug), Atezolizumab (Drug), Bevacizumab + Erlotinib (Drug), Entrectinib (Drug), Erlotinib (Drug), Trastuzumab + Pertuzumab… to Alectinib (Drug), Atezolizumab (Drug), Bevacizumab + Erlotinib (Drug), Entrectinib (Drug), Erlotinib (Drug), Pralsetinib (Drug)…
    • Site details revised at 1 of 31 sites
    v6
  6. Site details revised at 5 of 31 sitesv5
  7. Site details revised at 15 of 31 sitesv4
  8. Site details revised at 5 of 31 sitesv3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2022 to Sep 28, 2022
    • Site details revised at 31 of 31 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using targeted and/or immunotherapies outside of the approved indications via local clinical practice (Tier 1 \& 2) and clinical trials (Tier 3)
Trial Details
NCT Number NCT05525858
Lead Sponsor Seoul National University Bundang Hospital
Collaborators: Korean Cancer Study Group, Roche Pharma AG
Conditions
(from sponsor)		 Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
Related terms Neoplasm Metastasis
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov